Skip to main content
. Author manuscript; available in PMC: 2016 May 1.
Published in final edited form as: JAMA Intern Med. 2015 May 1;175(5):714–723. doi: 10.1001/jamainternmed.2015.132

Table 4.

New Multidrug-Resistant Organism (MDRO) Acquisitiona

Intervention Group Control Group Cluster- and Covariate-Adjusted Hazard Ratio (95% Cl) P Value
No. of Residents Device-days at Riskb Rate of New Acquisition per 1000 Device-days No. of Residents Device-days at Riskb Rate of New Acquisition per 1000 Device-days
New MRSA Acquisition (n = 248 Residents at Risk)c
54 8722 6.2 56 7115 7.9 0.78(0.65–0.95) .01
New VRE Acquisition (n = 258 Residents at Risk)c
22 12 756 1.7 26 11070 2.3 0.85(0.45–1.60) .61
First New Ciprofloxacin-Resistant or Ceftazidime-Resistant GNB Acquisition (n = 211 Residents at Risk)c,d
42 7524 5.6 35 5685 6.2 0.90(0.60–1.33) .59

Abbreviations: GNB, gram-negative bacilli; MRSA,methicillin-resistant Staphylococcus aureus; VRE, vancomycin-resistant enterococci.

a

New acquisition was assessed at the resident level (eg, a resident being negative for MRSA at baseline with a subsequent follow-up culture positive for MRSA at any anatomic site).

b

Once a participant was colonized with the MDRO, he or she did not contribute to at-risk days.

c

Excluded are participants with only 1 visit and those already colonized with the specific MDRO at baseline.

d

Included are first new ceftazidime-resistant GNB or ciprofloxacin-resistant GNB acquisition.